Hunan Centers for Disease Control and Prevention
Changsha, Hunan, China
NCT Number: NCT01827917
The objective of this study was to achieve the post-marketing protective effect research of Speeda® rabies vaccine for human use from Chengda Bio.
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 4
Changsha, Hunan, China
When found the injury who is bitten by the animal to three-level, the investigators would enroll the participant after explaining the protection and making him signed the informed consent. The patient would inject rabies vaccine as follow the national regulation, meanwhile the investigators would get the blood samples to detect whether the man-killer carries the rabies virus.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Injection on day 0、7、21
Time frame: 2 years
Whether or when would the patients develop symptoms after injured by the animals carrying the virus
Beijing Center for Disease Control and Prevention
Other Gov
Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01821911
Anti-D Antibodies, Rabies Vaccine Allergy
Zhaoqing, Guangdong, China
View Trial Details